GlassScriptPhysician profile
Gervaise L Gerstner
NPI 1770584195
$7,071.62
in general payments reported to CMS, 2019-2025
18 companies · $2,869 in 2025
The $2,869 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $657 · 2021: $627 · 2022: $988 · 2023: $286 · 2024: $896 · 2025: $2,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,050.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $2,892.43 | 2024-2025 | Daxxify |
| Merz North America, INC. | $1,410.77 | 2019-2023 | Xeomin |
| Allergan, INC. | $1,339.38 | 2019-2022 | |
| Abbvie INC. | $760.53 | 2023-2025 | |
| Galderma Laboratories, L.P. | $120.01 | 2021-2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $119.26 | 2019-2025 | Clear & Brilliant |
| Pfizer INC. | $98.50 | 2019-2024 | |
| Amgen INC. | $61.99 | 2023-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $47.30 | 2023 | Sotyktu |
| Vyne Pharmaceuticals INC. | $39.17 | 2020 | |
| Leo Pharma INC. | $36.92 | 2020-2025 | Anzupgo |
| Dermavant Sciences, INC. | $34.69 | 2023-2024 | Vtama |
| Organon LLC | $22.50 | 2025 | |
| Biofrontera INC. | $22.36 | 2021 | |
| Incyte Corporation | $19.66 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $17.32 | 2020 | |
| Epi Health, LLC | $14.83 | 2022 | |
| Strata Skin Sciences, INC. | $14.00 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gervaise Gerstner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.